120 filings
8-K
VSTM
Verastem Inc
24 May 24
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024
7:01am
8-K
VSTM
Verastem Inc
23 May 24
Submission of Matters to a Vote of Security Holders
5:24pm
8-K
VSTM
Verastem Inc
9 Apr 24
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
5:10pm
8-K
VSTM
Verastem Inc
29 Jan 24
Regulation FD Disclosure
4:01pm
8-K
VSTM
Verastem Inc
19 Jan 24
Submission of Matters to a Vote of Security Holders
7:54am
8-K
2o0e238
8 Jan 24
Entry into a Material Definitive Agreement
4:02pm
8-K
oci5fois 3t2rsjgdk
27 Oct 23
Departure of Directors or Certain Officers
4:41pm
8-K
sz01nzjb e4
28 Sep 23
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
2:27pm
8-K
khxs7
12 Sep 23
Corporate Presentation September 2023
4:08pm
8-K
ob6 fmmdric001
4 Aug 23
Departure of Directors or Certain Officers
4:40pm
8-K
r4xbd173egcg
12 Jul 23
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
8:50am
8-K
z8pybhb
21 Jun 23
Other Events
7:00am
8-K
ts4wy5 m7eg76
8 Jun 23
Corporate Presentation June 2023
5:24pm
8-K
s12t7o
31 May 23
Verastem Oncology Announces Reverse Stock Split
9:25am
8-K
6cuiwx m79dkwtzj5uee
25 May 23
Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer
5:18pm
8-K
whtgdkk
16 May 23
Submission of Matters to a Vote of Security Holders
7:26am
8-K
g0z0llr6
27 Mar 23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:30pm
8-K
acn mefmqklab8p
13 Mar 23
Regulation FD Disclosure
6:04am
8-K
vs7 6beqnot1a5uky
2 Feb 23
Results of Operations and Financial Condition
7:00am
8-K
q6580 cfee
25 Jan 23
Entry into a Material Definitive Agreement
8:18am